With advances in technology, it seems that ‘eternal youth’ is no longer just a fantasy in films or novels, but is scientifically possible.
For the first time, a human being has undergone a treatment designed to reverse the process of cellular aging. Scientists at a Boston-based American biotechnology company have developed a gene therapy aimed at rejuvenating aged or damaged cells in humans. The initial goal is more limited: to treat two serious diseases of the optic nerve, glaucoma and non-arteritic anterior ischemic optic neuropathy.
How their therapy works
Known as ER-100 (AAV2-OSK), it uses so-called OSK factors, three proteins – Oct4, Sox2 and Klf4 – to partially reprogram cells, erasing their age and restoring their function. After being tested in rodents and several mammals, the company announced that the first person has now received the treatment.
“This is the first epigenetic restoration candidate approved for clinical trials, and if successful, ER-100 treatment would represent the first case of cellular rejuvenation in humans”, the company said in a press release.
“Our research has suggested that aging is driven primarily by the loss of epigenetic information, not by irreversible damage”, explained David Sinclair, co-founder of Life Biosciences and professor of genetics at Harvard Medical School.
“This clinical study represents the first opportunity to test whether restoring this information can improve the course of human diseases”, he said.
The three proteins used in OSK gene therapy act like a reset button in cells, returning them to a more youthful state. A person’s DNA sequence remains largely stable throughout life, even as they age. However, the epigenetic code, which controls which genes are switched on or off, changes over time. These changes can result from lifestyle factors, such as smoking or alcohol consumption, aging, disease and injury, and can lead to harmful consequences, including cancer or neurological disorders.
Life Biosciences’ therapy targets these changes by directly delivering a set of genetic instructions: the three OSK proteins act as an “on” switch for targeted cells and reverse harmful changes that have accumulated over time.
This approach has been used in biology to transform ordinary cells into stem cells, a discovery that earned Sir John B. Gurdon and Shinya Yamanaka the 2012 Nobel Prize in Physiology or Medicine.






